



## ASX ANNOUNCEMENT

### **Lumos secures new contract manufacturing agreement and first purchase order with Micro-Pak®**

#### **Key Highlights**

- **Lumos secures supply contract to manufacture Micro-Pak’s Mold Analyzer system, enabling rapid on-site detection of mold for professional and consumer use, reducing turnaround times versus lab-based analysis**
- **The Micro-Pak Mold Analyzer system was developed by Lumos for Micro-Pak and comprises a novel mold detection test, Lumos digital camera reader, and a custom mobile application**
- **The new agreement is a follow-on contract for the Lumos Commercial Services Division which covers the production of custom readers and point-of-care tests**
- **First purchase order received for US\$250,000 pursuant to the three-year contract manufacturing agreement**

**MELBOURNE, Australia (8 April 2026)** – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”), a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that, leading on from the successful completion of product development activities for Micro-Pak Ltd (“Micro-Pak”), Lumos has secured a new contract manufacturing agreement for the manufacture of the Micro Pak Mold Analyzer system.

Micro-Pak is a global leader in mold and moisture prevention products that protect goods at every step of the supply chain. More information on Micro-Pak can be viewed at: [www.micropakltd.com](http://www.micropakltd.com).

The Mold Analyzer is a broad-spectrum mold detection test system, providing fast, reliable results for professional and consumer use. The Mold Analyzer rapid test cassette developed by Lumos for Micro-Pak is the first in the world to detect 56 mold species, providing full coverage for real-world environments. Combined with the Lumos proprietary camera reader and custom mobile application, the Mold Analyser provides consistent and full traceability of mold testing across the supply chain for manufacturers. The Mold Analyzer is also configurable for use as a stand-alone visual read test, providing a low-cost solution for consumer testing in the home. The Mold Analyzer product builds on Micro-Pak’s existing sample-collection and laboratory analysis service. More product information can be viewed at: [www.moldanalyzer.com](http://www.moldanalyzer.com).

The agreement builds on previous contract development work conducted by Lumos for Micro-Pak over the last 4 years and covers the ongoing manufacture of Mold Analyzer test cassettes and readers.

Lumos has received the first purchase order under the agreement, valued at US\$250,000. This new contract manufacturing agreement is for three years, with auto one year renewal periods.

Lumos Diagnostics CEO Doug Ward said: *“The signing of this contract manufacturing agreement further validates the services component of the broader Lumos business. This agreement demonstrates Lumos’ ability to convert substantial contract development programs into ongoing contract manufacturing agreements. We are proud to have worked with Micro-Pak to develop the Mold Analyzer from concept through to market launch. This first purchase order marks the start of commercial-scale manufacturing for Micro-Pak and represents valuable revenue for Lumos’ services business. We look forward to supporting Micro-Pak’s commercial success via our ongoing relationship.”*

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

#### **About Lumos Diagnostics,**

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).

#### **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

#### **Media Contacts:**

Tom Trezona – Australia

H^CK Acting Managing Director

[tom@hck.digital](mailto:tom@hck.digital)

+61 411 235 692

**Investor Contact:**

George Kopsiaftis

IR Specialist, IR Department

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 409 392 687

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne VIC 3000

[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)

+61 3 9087 1598

For personal use only